7150 related articles for article (PubMed ID: 2533598)
1. Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes.
Kradin R; Kurnick J; Gifford J; Pinto C; Preffer F; Lazarus D
J Clin Immunol; 1989 Sep; 9(5):378-85. PubMed ID: 2533598
[TBL] [Abstract][Full Text] [Related]
2. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
3. Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells: acute anergy to mitogens and recall antigens.
Ades EW; Bosse D; Orr S; Gillespie T
Pathobiology; 1990; 58(2):78-83. PubMed ID: 2360981
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens.
Kradin RL; Kurnick JT; Preffer FI; Dubinett SM; Dickersin GR; Pinto C
Clin Immunol Immunopathol; 1989 Feb; 50(2):184-95. PubMed ID: 2783665
[TBL] [Abstract][Full Text] [Related]
5. The effects of blockade of interleukin 2 receptors and interleukin 4 receptors on cytokine production.
Lai KN; Leung JC; Li PK; Larche M; Ritter MA
APMIS; 1991 May; 99(5):434-42. PubMed ID: 1904250
[TBL] [Abstract][Full Text] [Related]
6. Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes.
Conlon KC; Ochoa AC; Kopp WC; Ortaldo JR; Urba WJ; Longo DL; Young HA
J Immunol; 1992 Nov; 149(10):3278-89. PubMed ID: 1358968
[TBL] [Abstract][Full Text] [Related]
7. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
8. Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.
Treisman J; Higuchi CM; Thompson JA; Gillis S; Lindgren CG; Kern DE; Ridell SR; Greenberg PD; Fefer A
Cancer Res; 1990 Feb; 50(4):1160-4. PubMed ID: 2153452
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of interleukin-2 and apha-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes.
Sfikakis PP; Souliotis VL; Katsilambros N; Markakis K; Vaiopoulos G; Tsokos GC; Panayiotidis P
Clin Immunol Immunopathol; 1996 Apr; 79(1):43-9. PubMed ID: 8612350
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects.
Adler A; Schachter J; Barenholz Y; Bar LK; Klein T; Korytnaya R; Sulkes A; Michowiz R; Cohen Y; Kedar I
Cancer Biother; 1995; 10(4):293-306. PubMed ID: 8590895
[TBL] [Abstract][Full Text] [Related]
12. Alterations in pulmonary function in cancer patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2.
Lazarus DS; Kurnick JT; Kradin RL
Am Rev Respir Dis; 1990 Jan; 141(1):193-8. PubMed ID: 2297177
[TBL] [Abstract][Full Text] [Related]
13. Selective deficiency in IL-2 production and refractoriness to extrinsic IL-2 in immunodeficiency with hyper-IgM.
Ohno T; Fujii H; Kanoh T; Uchino H; Kuribayashi K; Masuda T; Watanabe Y
Clin Immunol Immunopathol; 1987 Dec; 45(3):471-80. PubMed ID: 2445512
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.
Voss SD; Hank JA; Nobis CA; Fisch P; Sosman JA; Sondel PM
Cancer Immunol Immunother; 1989; 29(4):261-9. PubMed ID: 2787694
[TBL] [Abstract][Full Text] [Related]
15. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
J Hematother; 1997 Jun; 6(3):253-60. PubMed ID: 9234180
[TBL] [Abstract][Full Text] [Related]
16. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.
Kradin RL; Kurnick JT; Lazarus DS; Preffer FI; Dubinett SM; Pinto CE; Gifford J; Davidson E; Grove B; Callahan RJ
Lancet; 1989 Mar; 1(8638):577-80. PubMed ID: 2564111
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma.
Dubinett SM; Kurnick JT; Kradin RL
Am J Respir Cell Mol Biol; 1989 Nov; 1(5):361-9. PubMed ID: 2517774
[TBL] [Abstract][Full Text] [Related]
19. [Characterization of autologous-tumor specific cytotoxic T cells induced by means of butanol-extracted soluble antigen from T lymphocytes in colon cancer patients].
Hamagashira K
Nihon Geka Gakkai Zasshi; 1993 Feb; 94(2):128-37. PubMed ID: 8464410
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 in combination with vinblastine for metastatic renal cancer: cytolytic activity of peripheral blood lymphocytes.
Indrová M; Bubeník J; Jakoubková J; Símová J; Jandlová T; Helmichová E; Benesová K; Hesová M; Stáhalová V
Neoplasma; 1994; 41(4):197-200. PubMed ID: 7935991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
